TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $100
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
TD Cowen analyst Tara Bancroft maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $90 to $100.
TD Cowen analyst Tara Bancroft maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $90 to $100.